Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

Detalles Bibliográficos
Publicado en:Journal of Clinical Oncology Vol. 40; no. 28; pp. 3289 - 3301
Autores principales: Thiel, Kristina W., Devor, Eric J., Filiaci, Virginia L., Mutch, David, Moxley, Katherine, Alvarez Secord, Angeles, Tewari, Krishnansu S., McDonald, Megan E., Mathews, Cara, Cosgrove, Casey, Dewdney, Summer, Aghajanian, Carol, Samuelson, Megan I., Lankes, Heather A., Soslow, Robert A., Leslie, Kimberly K.
Formato: clinical trial pictorial research tables/charts randomized controlled trial Journal Article
Publicado: American Society of Clinical Oncology 10/1/2022
Acceso en línea:Ver este registro en EBSCOhost